Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GamaMabs Pharma SA

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

ImmunoGen Inc

Kolltan Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Sorrento Therapeutics Inc

Symphogen A/S

Takis Srl

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Overview 9

Therapeutics Development 10

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Products under Development by Stage of Development 10

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Products under Development by Therapy Area 11

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Products under Development by Indication 12

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Products under Development by Companies 16

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Products under Development by Universities/Institutes 21

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 30

AstraZeneca Plc 30

AVEO Pharmaceuticals Inc 31

Daiichi Sankyo Company Ltd 32

Etubics Corp 33

F. Hoffmann-La Roche Ltd 34

GamaMabs Pharma SA 35

GlaxoSmithKline Plc 36

Hanmi Pharmaceuticals Co Ltd 37

ImmunoGen Inc 38

Kolltan Pharmaceuticals Inc 39

Merrimack Pharmaceuticals Inc 40

Merus NV 41

Novartis AG 42

Shanghai Fosun Pharmaceutical (Group) Co Ltd 43

Sorrento Therapeutics Inc 44

Symphogen A/S 45

Takis Srl 46

XuanZhu Pharma Co Ltd 47

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Drug Profiles 48

AV-203 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

AV-353 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

BA-0702 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

elgemtumab - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ETBX-031 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

FCN-411 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

GSK-2849330 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

H4B-121 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

huHER3-8 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

istiratumab - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

KTN-3379 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

lumretuzumab - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

MCLA-125 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

patritumab - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

pirotinib - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

poziotinib - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

sapitinib - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

seribantumab - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

sirotinib - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Sym-013 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

TK-003 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Vaccine to Target HER1, HER2 and HER3 for Oncology - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Dormant Projects 89

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Discontinued Products 93

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Featured News & Press Releases 96

Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016 96

Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer 96

Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress 97

Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491) 98

Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer 98

Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer 99

Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 100

May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer 102

May 18, 2016: Merrimack to Present Data on Seribantumab at the 2016 American Society of Clinical Oncology Annual Meeting 102

May 18, 2016: Kolltan Pharmaceuticals to Report KTN3379 Clinical Data in an Oral Presentation at the Upcoming 2016 American Society of Clinical Oncology Annual Meeting 103

May 17, 2016: Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series 104

May 02, 2016: AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH 105

Apr 20, 2016: Kolltan Pharmaceuticals Presents Preclinical Data on KTN3379 at the 2016 American Association for Cancer Research Annual Meeting 105

Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 107

Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 107

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Products under Development by Companies, H2 2016 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by AstraZeneca Plc, H2 2016 30

Pipeline by AVEO Pharmaceuticals Inc, H2 2016 31

Pipeline by Daiichi Sankyo Company Ltd, H2 2016 32

Pipeline by Etubics Corp, H2 2016 33

Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 34

Pipeline by GamaMabs Pharma SA, H2 2016 35

Pipeline by GlaxoSmithKline Plc, H2 2016 36

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 37

Pipeline by ImmunoGen Inc, H2 2016 38

Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 39

Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 40

Pipeline by Merus NV, H2 2016 41

Pipeline by Novartis AG, H2 2016 42

Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2016 43

Pipeline by Sorrento Therapeutics Inc, H2 2016 44

Pipeline by Symphogen A/S, H2 2016 45

Pipeline by Takis Srl, H2 2016 46

Pipeline by XuanZhu Pharma Co Ltd, H2 2016 47

Dormant Projects, H2 2016 89

Dormant Projects (Contd..1), H2 2016 90

Dormant Projects (Contd..2), H2 2016 91

Dormant Projects (Contd..3), H2 2016 92

Discontinued Products, H2 2016 93

Discontinued Products (Contd..1), H2 2016 94

Discontinued Products (Contd..2), H2 2016 95

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports